TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03516929

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: carotid duplex, both LL arterial duplex
Description: assessment of carotid stenosis and lower limb peripheral ischemia.

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: carotid duplex, both LL arterial duplex
Description: assessment of carotid stenosis and lower limb peripheral ischemia.
Study: NCT03716700

Intervention type: BIOLOGICAL
Intervention: CUVITRU
Description: CUVITRU

Intervention type: BIOLOGICAL
Intervention: CUVITRU
Description: CUVITRU

Intervention type: BIOLOGICAL
Intervention: CUVITRU
Description: CUVITRU
Study: NCT00976612

Intervention type: DRUG
Intervention: Nilotinib
Description: Nilotinib 400mg bid daily
Study: NCT02757235

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Irrigation fluid of body temperature
Description: Irrigation fluid of body temperature will be used during burr hole evacuation of chronic subdural hematoma

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Irrigation fluid of room temperature
Description: Irrigation fluid of room temperature will be used during burr hole evacuation of chronic subdural hematoma.
Study: NCT00906204

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single-dose rabbit Anti-thymocyte Globulin induction
Description: 6 mg of rATG administered in a single dose on the day of kidney transplantation

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Divided-dose rabbit Anti-thymocyte Globulin induction
Description: 6 mg/kg total rabbit Anti-thymocyte Globulin dose administered as 1.5 mg/kg doses on 4 sequential days, beginning on the day of kidney transplantation.
Study: NCT03333343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGF816
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGF816
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGF816
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGF816
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGF816
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGF816
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGF816
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGF816
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGF816
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGF816
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trametinib
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trametinib
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribociclib
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribociclib
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXH254
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXH254
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXH254
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Study Drug
Study: NCT01029275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-treatment with octreotide
Description: Pre-treatment with octreotide
Study: NCT00911170

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegfilgrastim
Description: Administered as a single 6 mg subcutaneous injection using a pre-filled syringe. There will be no dosage adjustments for investigational product.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as a single subcutaneous injection using a pre-filled syringe.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: 5 mg/kg by intravenous (IV) infusion on day 1 of each 14-day cycle.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: 5 mg/kg by intravenous (IV) infusion on day 1 of each 14-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard Chemotherapy
Description: Each participant received one of the following chemotherapy regimens at the discretion of treating physician:~FOLFOX: Oxaliplatin, leucovorin, and 5-fluorouracil; FOLFIRI: Irinotecan, leucovorin and 5-flurouracil.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard Chemotherapy
Description: Each participant received one of the following chemotherapy regimens at the discretion of treating physician:~FOLFOX: Oxaliplatin, leucovorin, and 5-fluorouracil; FOLFIRI: Irinotecan, leucovorin and 5-flurouracil.
Study: NCT02170376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: BIA 9-1067 25 mg and 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: BIA 9-1067 25 mg and 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: BIA 9-1067 25 mg and 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entacapone
Description: Entacapone (ENT), over-encapsulated tablet 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PLC, placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PLC, placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PLC, placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PLC, placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PLC, placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa
Description: Levodopa/carbidopa, tablet 100/25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa
Description: Levodopa/carbidopa, tablet 100/25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa
Description: Levodopa/carbidopa, tablet 100/25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa
Description: Levodopa/carbidopa, tablet 100/25 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levodopa/carbidopa
Description: Levodopa/carbidopa, tablet 100/25 mg
Study: NCT02435186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: p53 gene
Description: p53 gene will be given intraperitoneally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 150 mg/m\^2 cisplatin will be given intraperitoneally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 150 mg/m\^2 cisplatin will be given intraperitoneally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel (175 mg/m2, 3 h) will be given by iv

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel (175 mg/m2, 3 h) will be given by iv
Study: NCT01841099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine
Description: Mesalamine granules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo granules
Description: Provided by Ferring Pharma
Study: NCT03841461

Intervention type: OTHER
Intervention: International Physical Activity Questionnaire-Short Form
Description: IPAQ has been developed to obtain valid and comparable information about the level of physical activity based on individual reports on daily physical activity in the international arena. This form consists of 7 questions; provides information about time spent in walking, moderate and violent activities, and time spent sitting. The calculation of the total score of the short form includes total of duration and frequency whom walking, moderate activity and severe activity. The energy required for the activities is calculated by the MET-minute score.Standard MET values for these activities has been established. These; Walking = 3.3 MET;Moderate Severe Physical Activity = 4.0 MET;Severe Physical Activity = 8.0 MET;Seating = 1.5 MET.Classification is based on the numerical data obtained.Accordingly,there are 3 activity levels: Inactive,minimal active and very active.

Intervention type: OTHER
Intervention: The Pittsburgh Sleep Quality Index
Description: It is a scale that provides information about the sleep quality of the individuals and the type and severity of the sleep disorder in the last month. It consists of 24 questions, 19 of which are evaluated. The PSQI consists of 1 total score and 7 sub-dimensions (subjective sleep quality, sleep latency, sleep duration, usual sleep efficiency, sleep disturbance, sleep medication use, daytime dysfunction). Each item in the scale has a value between 0 (no distress) and 3 (serious distress). The sum of the scores related to the seven sub-dimensions gives the total PSQI score. The score of each sub-dimension ranges from 0 to 3. The total PSQI score ranged from 0 to 21. While the sleep quality of the patients with a total score of 5 and below is considered as 'good'; \>5 refers to poor sleep quality.

Intervention type: OTHER
Intervention: The Fatigue Severity Scale
Description: Each question on this scale, which is composed of Likert type questions: 1.I strongly disagree 2.I do not agree 3.No tend to disagree 4. Indefinitely. The score of the scale, which consists of 9 questions, varies between 9-63. People are asked to mark the appropriate options for each question taking into account their status in the last 1 month period.

Intervention type: OTHER
Intervention: General Information Form
Description: A form, which is prepared by us, including the purpose of the study, demographic information, daily working hours and assignment durations.
Study: NCT02166346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalfampridine
Description: Dalfampridine 10 mg twice daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalfampridine
Description: Dalfampridine 10 mg twice daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo pill 1 tablet twice daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo pill 1 tablet twice daily for 8 weeks
Study: NCT03591406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Dosage Form: Injection, Sterile FCM solution as a 5% w/v iron solution in water for injection Strength: 10 mL vials containing 500 mg iron per vial Dosage: 500mg/week or 1000mg/week (based on subject BW and Hb value at screening) Route of administration: IV injection (undiluted solution) or drip infusion (500 mg iron diluted in 100 mL 0.9% w/v physiological saline or 1,000 mg iron diluted in 250 mL 0.9% w/v physiological saline) Dosing schedules: baseline (Day 1) and, if required, at Day 8 and Day 15.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron sucrose
Description: Dosage Form: Sterile solution for injection containing 2% w/v iron Strength: 5 mL ampoules containing 100 mg iron per ampoule Dosage: single doses of IS of 200mg iron based on the formula of Ganzoni: Cumulative iron deficit \[mg\] = BW \[kg\] x (target Hb- actual Hb) \[g/dL\] x 2.4 + 500 mg, up to 11 IS injections will be given Route of administration: IV injection or drip infusion Dosing schedules: three times a week, with an initial dose at baseline and will receive iron, as per approved label, until the subject has received the calculated iron dose.
Study: NCT01710501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: Grazoprevir tablet, orally, once per day at assigned dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: Grazoprevir tablet, orally, once per day at assigned dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: Grazoprevir tablet, orally, once per day at assigned dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegylated interferon alfa-2b
Description: 1.5 mcg/kg/week, administered as a weekly subcutaneous (SC) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegylated interferon alfa-2b
Description: 1.5 mcg/kg/week, administered as a weekly subcutaneous (SC) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegylated interferon alfa-2b
Description: 1.5 mcg/kg/week, administered as a weekly subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin capsule, orally, twice daily, at a dose of 800 to 1400 mg based on participant weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin capsule, orally, twice daily, at a dose of 800 to 1400 mg based on participant weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin capsule, orally, twice daily, at a dose of 800 to 1400 mg based on participant weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match grazoprevir tablets to maintain dose blinding

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match grazoprevir tablets to maintain dose blinding

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match grazoprevir tablets to maintain dose blinding
Study: NCT02151058

Intervention type: DRUG
Group type: OTHER
Intervention: Colgate® Regular Cavity Protection
Description: Brushing twice daily with an ADA - Accepted fluoride - containing dentifrice (Colgate Cavity Protection)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Mouth Rinse
Description: Brushing twice daily with an ADA - Accepted containing toothpaste, followed by rinsing with 10 mL for 60 seconds with the investigational product.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Crest® 3D White Multi-Care Whitening Rinse, Glamorous White, Fresh Mint
Description: Brushing twice daily with an ADA - Accepted containing toothpaste, followed by rinsing with 15 mL for 60 seconds with the active comparator.
Study: NCT04645758

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling and Extra corporeal Shock wave therapy
Description: 5 mins of dry needling and 1250 pulses of shockwave therapy on dominant forearm muscles

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling and Extra corporeal Shock wave therapy
Description: 5 mins of dry needling and 1250 pulses of shockwave therapy on dominant forearm muscles
Study: NCT00809185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Patients will receive monotherapy with RAD001(everolimus)for 21 days within the 28 day cycle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Laboratory correlates (cytotoxic t cell populations, S6K1 levels, GSTT-1 mutations, and the presence or absence of HLA-DR15) will be assessed to see if any of these correlates correspond to response.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow aspirate/biopsy
Description: Bone marrow aspirate and biopsy with cytogenetics should be obtained within 4 weeks prior to starting drug and at week 33. A bone marrow aspirate and biopsy should also be obtained for patients going off study prior to week 33 (including cytogenetics). The percentage of blasts on the aspirate should be used to determine the IPSS score.
Study: NCT03453164

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy of 22.5 Gy/5 fractions/5 days was given to a symptomatic lesion or the largest asymptomatic lesion suitable for irradiation from Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab was administered intravenously starting on Day 15-22 at a dose of 3 mg/kg (body weight) or 240 mg/body every 2 weeks to a total of 6 courses of administration.
Study: NCT04909463

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chest Splint
Description: Those receiving intervention will be given the Duracore chest splint for use throughout the trial.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chest Splint
Description: Those receiving intervention will be given the Duracore chest splint for use throughout the trial.
Study: NCT01060332

Intervention type: OTHER
Intervention: Body Constitution Questionnaire
Description: Body Constitution Questionnaire was a tool for the study of objective evaluation of diagnostics of Traditional Chinese Medicine. It has been well developed with good validation and consistency.
Study: NCT02973711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib 300 mg BID
Study: NCT04060498

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Description: MBI-p focuses on simplicity, for both facilitators and patients; and use acceptance and embracing attitude for fear and sadness. The ultimate aims are to help patients achieve a greater sense of peace and calmness, and facilitate participants in handling everyday stress and conflicts.
Study: NCT02973711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib, 10, 15 or 20mg BID
Study: NCT04060498

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducation intervention
Description: Psychoeducation focuses on disseminating information about common mental disorders, psychosis (its causes, risk factors and trajectory), and methods of treatment for psychosis.
Study: NCT00262340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non invasive measurement of airway inflammation
Description: Airway inflammation will be assessed non-invasively using induced sputum and exhaled nitric oxide. In the active group the results of these tests will be used to determine if asthma treatment should be changed. In the comparator group treatment changes will be based according to conventional symptom based management

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non invasive measurement of airway inflammation
Description: Airway inflammation will be assessed non-invasively using induced sputum and exhaled nitric oxide. In the active group the results of these tests will be used to determine if asthma treatment should be changed. In the comparator group treatment changes will be based according to conventional symptom based management
Study: NCT00474487

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal ACWY Polysaccharide Vaccine
Description: One dose of the licensed meningococcal ACWY polysaccharide vaccine was administered by subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY CRM (19 to 55 years)
Description: One dose of the Novartis meningococcal ACWY conjugate vaccine was administered by intramuscular injection to subjects 19 years to 55 years of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal ACWY Conjugate Vaccine
Description: One dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novartis MenACWY Vaccine (56 to 65 Years)
Description: One dose of the Novartis meningococcal ACWY conjugate vaccine was administered by intramuscular injection administered to subjects 56 years to 65 years of age.
Study: NCT02336152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anaesthesia, Teles Pro, Body suit

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anaesthesia, Teles Pro, Body suit
Study: NCT02132962

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Amino acid infusion

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Amino acid infusion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bloodsamples, Biopsies.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bloodsamples, Biopsies.
Study: NCT02214797

Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A, Lotrafilcon B , Senofilcon A
Study: NCT00427895

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (13vPnC)
Description: 0.5 mL dose administered on day 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 23-valent Pneumococcal Polysaccharide Vaccine (23vPS)
Description: 0.5 mL dose administered on day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (13vPnC)
Description: 0.5 mL dose administered on day 1
Study: NCT02214797

Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A, Lotrafilcon B , Senofilcon A

Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A, Lotrafilcon B , Senofilcon A

Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A, Lotrafilcon B , Senofilcon A
Study: NCT04286984

Intervention type: OTHER
Intervention: unified protocol of Patient Blood Management measure
Description: upPBM description: After performing a laboratory work-up 2 to 4 weeks before surgery, preoperative iron supplementation in case of iron deficiency anemia at least 7 days before surgery was recommended. Preoperative anemia was defined by a Hb level \< 13 g/dL for both sexes. In anemic patients, iron status study was recommended and iron supplementation with intravenous iron was indicated if Hb\<12g/dL and/or ferritin \<300 mg/l. Intravenous iron (ferric sucrose or carboxymaltose) was administrated with the goal of recovering iron deficit, calculated using the Ganzoni formula or by the simplified strategy, only available for ferric carboxymaltose. Recommended transfusion triggers were: Hb \< 9 g/dL for patients with risk factors and/or anemia symptoms; and Hb \< 7 g/dL for the rest of patients in absence of active bleeding.
Study: NCT01887327

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Phototherapy
Description: Phototherapy starts within 30 minutes before or after injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: Phototherapy starts within 30 minutes before or after injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: Phototherapy starts within 30 minutes before or after injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stannsoporfin
Description: Stannsoporfin (3.0 or 4.5 mg/kg) administered by intramuscular (IM) injection (a shot in the muscle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stannsoporfin
Description: Stannsoporfin (3.0 or 4.5 mg/kg) administered by intramuscular (IM) injection (a shot in the muscle)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered by IM injection